Loading…

Blood ACE2 Protein Level Correlates with COVID-19 Severity

ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical reco...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-09, Vol.24 (18), p.13957
Main Authors: Shevchuk, Oksana, Pak, Anastasia, Palii, Svitlana, Ivankiv, Yana, Kozak, Kateryna, Korda, Mykhaylo, Vari, Sandor G
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3
cites cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3
container_end_page
container_issue 18
container_start_page 13957
container_title International journal of molecular sciences
container_volume 24
creator Shevchuk, Oksana
Pak, Anastasia
Palii, Svitlana
Ivankiv, Yana
Kozak, Kateryna
Korda, Mykhaylo
Vari, Sandor G
description ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p < 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.
doi_str_mv 10.3390/ijms241813957
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10530872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A771803850</galeid><sourcerecordid>A771803850</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</originalsourceid><addsrcrecordid>eNptkctLxDAQxosouK4evRe8eKnm0aSJF1nra2FBwcc1tOnUzdI2mrSK_73RXdQVmUOGfL_5JpOJon2MjiiV6NgsWk9SLDCVLNuIRjglJEGIZ5u_8u1ox_sFQoQSJkfRyVljbRVP8gsS3zrbg-niGbxCE-fWOWiKHnz8Zvp5nN88Ts8TLOO7IDvTv-9GW3XReNhbnePo4fLiPr9OZjdX03wyS3TKUZ8wJlMiEEYF5yAzKEXKOGZQ1hlojDjXIrye1wSTqiaaYloKQatKSJ5KToGOo9Ol7_NQtlBp6HpXNOrZmbZw78oWRq0rnZmrJ_uqMGIUiYwEh8OVg7MvA_hetcZraJqiAzt4RUSGwqdhwQJ68Add2MF1Yb5AcUkFIQz9UE9FA8p0tQ2N9aepmmQZFoiKL-roHypEBa3RtoPahPu1gmRZoJ313kH9PSRG6nPFam3F9AOrEZUn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869382250</pqid></control><display><type>article</type><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</creator><creatorcontrib>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</creatorcontrib><description>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p &lt; 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms241813957</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Biological products ; Blood pressure ; Blood proteins ; Body mass index ; Comorbidity ; COVID-19 ; Development and progression ; Diabetes ; Enzyme-linked immunosorbent assay ; Enzymes ; Hospitalization ; Hypertension ; Infections ; Lung diseases ; Medical personnel ; Medical records ; Obesity ; Overweight ; Pandemics ; Proteins ; Respiratory diseases ; Risk factors ; Severe acute respiratory syndrome coronavirus 2 ; Viruses</subject><ispartof>International journal of molecular sciences, 2023-09, Vol.24 (18), p.13957</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</citedby><cites>FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</cites><orcidid>0000-0003-2473-6381 ; 0000-0002-5328-4647 ; 0000-0003-3305-6265 ; 0000-0002-6066-5165</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2869382250/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2869382250?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,38493,43871,44566,53766,53768,74155,74869</link.rule.ids></links><search><creatorcontrib>Shevchuk, Oksana</creatorcontrib><creatorcontrib>Pak, Anastasia</creatorcontrib><creatorcontrib>Palii, Svitlana</creatorcontrib><creatorcontrib>Ivankiv, Yana</creatorcontrib><creatorcontrib>Kozak, Kateryna</creatorcontrib><creatorcontrib>Korda, Mykhaylo</creatorcontrib><creatorcontrib>Vari, Sandor G</creatorcontrib><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><title>International journal of molecular sciences</title><description>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p &lt; 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</description><subject>Biological products</subject><subject>Blood pressure</subject><subject>Blood proteins</subject><subject>Body mass index</subject><subject>Comorbidity</subject><subject>COVID-19</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Hospitalization</subject><subject>Hypertension</subject><subject>Infections</subject><subject>Lung diseases</subject><subject>Medical personnel</subject><subject>Medical records</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Pandemics</subject><subject>Proteins</subject><subject>Respiratory diseases</subject><subject>Risk factors</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viruses</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNptkctLxDAQxosouK4evRe8eKnm0aSJF1nra2FBwcc1tOnUzdI2mrSK_73RXdQVmUOGfL_5JpOJon2MjiiV6NgsWk9SLDCVLNuIRjglJEGIZ5u_8u1ox_sFQoQSJkfRyVljbRVP8gsS3zrbg-niGbxCE-fWOWiKHnz8Zvp5nN88Ts8TLOO7IDvTv-9GW3XReNhbnePo4fLiPr9OZjdX03wyS3TKUZ8wJlMiEEYF5yAzKEXKOGZQ1hlojDjXIrye1wSTqiaaYloKQatKSJ5KToGOo9Ol7_NQtlBp6HpXNOrZmbZw78oWRq0rnZmrJ_uqMGIUiYwEh8OVg7MvA_hetcZraJqiAzt4RUSGwqdhwQJ68Add2MF1Yb5AcUkFIQz9UE9FA8p0tQ2N9aepmmQZFoiKL-roHypEBa3RtoPahPu1gmRZoJ313kH9PSRG6nPFam3F9AOrEZUn</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Shevchuk, Oksana</creator><creator>Pak, Anastasia</creator><creator>Palii, Svitlana</creator><creator>Ivankiv, Yana</creator><creator>Kozak, Kateryna</creator><creator>Korda, Mykhaylo</creator><creator>Vari, Sandor G</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2473-6381</orcidid><orcidid>https://orcid.org/0000-0002-5328-4647</orcidid><orcidid>https://orcid.org/0000-0003-3305-6265</orcidid><orcidid>https://orcid.org/0000-0002-6066-5165</orcidid></search><sort><creationdate>20230901</creationdate><title>Blood ACE2 Protein Level Correlates with COVID-19 Severity</title><author>Shevchuk, Oksana ; Pak, Anastasia ; Palii, Svitlana ; Ivankiv, Yana ; Kozak, Kateryna ; Korda, Mykhaylo ; Vari, Sandor G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biological products</topic><topic>Blood pressure</topic><topic>Blood proteins</topic><topic>Body mass index</topic><topic>Comorbidity</topic><topic>COVID-19</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Hospitalization</topic><topic>Hypertension</topic><topic>Infections</topic><topic>Lung diseases</topic><topic>Medical personnel</topic><topic>Medical records</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Pandemics</topic><topic>Proteins</topic><topic>Respiratory diseases</topic><topic>Risk factors</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shevchuk, Oksana</creatorcontrib><creatorcontrib>Pak, Anastasia</creatorcontrib><creatorcontrib>Palii, Svitlana</creatorcontrib><creatorcontrib>Ivankiv, Yana</creatorcontrib><creatorcontrib>Kozak, Kateryna</creatorcontrib><creatorcontrib>Korda, Mykhaylo</creatorcontrib><creatorcontrib>Vari, Sandor G</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shevchuk, Oksana</au><au>Pak, Anastasia</au><au>Palii, Svitlana</au><au>Ivankiv, Yana</au><au>Kozak, Kateryna</au><au>Korda, Mykhaylo</au><au>Vari, Sandor G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood ACE2 Protein Level Correlates with COVID-19 Severity</atitle><jtitle>International journal of molecular sciences</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>24</volume><issue>18</issue><spage>13957</spage><pages>13957-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>ACE2’s impact on the severity of COVID-19 is widely discussed but still controversial. To estimate its role in aspects of the main risk factors and comorbidities, we involved post-COVID-19 patients in Ternopil region (Ukraine). The recruitment period was from July 2020 to December 2021. Medical records, treatment modalities, and outcomes were recorded and analyzed. The serum human ACE2 protein was measured with Cusabio ELISA kits (Houston, TX, USA). Statistical analysis was performed with SPSS21.0 software (SPSS Inc., Chicago, IL, USA). The level of the ACE2 serum protein was significantly higher (p &lt; 0.001) in patients with mild symptoms compared to a more severe course of the disease, and inversely had changed from 1 to 90 days after recovery. In patients with mild COVID-19, ACE2 levels significantly decreased over time, while among critical patients, it increased by 34.1 percent. Such results could be explained by ACE2 shedding from tissues into circulation. Loss of the membrane-bound form of the enzyme decreases the virus’ entry into cells. Our studies did not identify a sex-related ACE2 serum level correlation. The most common comorbidities were hypertension, cardiovascular diseases, respiratory diseases, and diabetes mellitus. All abovementioned comorbidities except respiratory diseases contribute to the severity of the disease and correlate with ACE2 blood serum levels.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/ijms241813957</doi><orcidid>https://orcid.org/0000-0003-2473-6381</orcidid><orcidid>https://orcid.org/0000-0002-5328-4647</orcidid><orcidid>https://orcid.org/0000-0003-3305-6265</orcidid><orcidid>https://orcid.org/0000-0002-6066-5165</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2023-09, Vol.24 (18), p.13957
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10530872
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database
subjects Biological products
Blood pressure
Blood proteins
Body mass index
Comorbidity
COVID-19
Development and progression
Diabetes
Enzyme-linked immunosorbent assay
Enzymes
Hospitalization
Hypertension
Infections
Lung diseases
Medical personnel
Medical records
Obesity
Overweight
Pandemics
Proteins
Respiratory diseases
Risk factors
Severe acute respiratory syndrome coronavirus 2
Viruses
title Blood ACE2 Protein Level Correlates with COVID-19 Severity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A48%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20ACE2%20Protein%20Level%20Correlates%20with%20COVID-19%20Severity&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Shevchuk,%20Oksana&rft.date=2023-09-01&rft.volume=24&rft.issue=18&rft.spage=13957&rft.pages=13957-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms241813957&rft_dat=%3Cgale_pubme%3EA771803850%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c460t-559428010a66e97eb845615ebf7ec1066c83396f212df2c313b883dd8964963e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2869382250&rft_id=info:pmid/&rft_galeid=A771803850&rfr_iscdi=true